US-China trade war provides opportunity for Indian pharma, says analyst

It is been more than a year since China and the USA are engaged in an escalating trade battle involving mutual placement of punitive tariffs. However, in the latest round, the USA has excluded pharmaceuticals as a category from the list of trade war tariffs.

This presents an opportunity for the Indian pharmaceutical industry, according to data and analytics company GlobalData.

Both China and the USA are key markets for India from the pharma industry perspective. India has done exceptionally well in the US market, whereas it is still in the stage of exploring the Chinese market. GlobalData forecasts the Indian pharmaceutical market to increase from nearly $30.8 billion in 2018 to more than $38.3 billion by 2022.